Bioventus Inc. (NASDAQ:BVS) Stock Has Average Price Target of $16.80 According to Brokerages

Shares of Bioventus Inc. (NASDAQ:BVS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $16.80.

BVS has been the subject of a number of analyst reports. Canaccord Genuity Group increased their target price on shares of Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Craig Hallum restated a “buy” rating and set a $18.00 price target on shares of Bioventus in a report on Thursday, August 6th. Weiss Ratings raised Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 price objective on shares of Bioventus in a report on Monday, August 17th. Finally, Barrington Research set a $18.00 price objective on Bioventus in a research report on Thursday, August 6th.

Get Bioventus alerts:

Check Out Our Latest Stock Analysis on BVS

Institutional Trading of Bioventus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd increased its position in Bioventus by 17,156.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after purchasing an additional 5,490 shares during the period. Diversified Trust Co purchased a new stake in shares of Bioventus in the 1st quarter worth about $100,000. State of Wyoming lifted its position in shares of Bioventus by 45.5% in the 4th quarter. State of Wyoming now owns 38,357 shares of the company’s stock worth $285,000 after purchasing an additional 11,989 shares during the period. Quantinno Capital Management LP lifted its position in shares of Bioventus by 119.6% in the 1st quarter. Quantinno Capital Management LP now owns 72,023 shares of the company’s stock worth $658,000 after purchasing an additional 39,222 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Bioventus by 11.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 79,913 shares of the company’s stock valued at $730,000 after purchasing an additional 8,225 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Stock Performance

NASDAQ:BVS opened at $13.13 on Monday. The firm has a market capitalization of $1.10 billion, a P/E ratio of 17.05, a P/E/G ratio of 1.67 and a beta of 0.64. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83. The company has a fifty day moving average of $13.70 and a 200 day moving average of $11.21. Bioventus has a 52 week low of $6.37 and a 52 week high of $15.89.

Bioventus (NASDAQ:BVS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The business had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, research analysts predict that Bioventus will post 0.79 earnings per share for the current year.

Bioventus Company Profile

(Get Free Report)

Bioventus Inc (NASDAQ:BVS) is a medical device company focused on therapies for musculoskeletal conditions. The company develops, manufactures and commercializes products intended to support bone healing, improve joint health and assist with surgical and rehabilitative care.

Its portfolio includes bone-healing systems such as EXOGEN, an ultrasound device used to support fracture healing, as well as osteoarthritis treatments including DUROLANE and GELSYN-3 hyaluronic acid injections. Bioventus also offers surgical technologies through its Misonix business, including ultrasonic systems used in procedures involving soft tissue and bone, and rehabilitation and neurostimulation products through its Bioness business.

Bioventus was formed in 2011 following the separation of a bone-healing business from Smith & Nephew and is headquartered in Durham, North Carolina.

Featured Stories

• Five stocks we like better than Bioventus
• Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
• The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
• McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
• MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?

Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.